Endo subsidiary to acquire Indevus

CHADDS FORD, Pa. Endo Pharmaceuticals will acquire Indevus Pharmaceuticals, Endo announced Thursday.

Endo said its subsidiary, BTB Purchaser, had completed a tender offer to acquire 89.15% of shares in Indevus, and that it will complete its acquisition by merging BTB into Indevus, with Indevus continuing as a wholly owned subsidiary of Endo.

Exact financial terms of the deal were not disclosed, though the merger is expected to occur within the next several days, Endo said.